江中药业董事会审计委员会 2024 年度履职情况报告 2024 年度（以下简称"报告期"），江中药业股份有限公司 （以下简称"公司"）董事会审计委员会委员，根据《公司法》 《上市公司治理准则》等有关规定，以及《公司章程》《董事会审 计委员会实施细则》等相关要求，本着勤勉尽责的原则，认真履行 职责，现将 2024 年度的履职情况报告如下： 一、审计委员会基本情况 公司董事会下设的审计委员会由 3 名成员组成，其中 2 名为独立 董事，并由独立董事中的会计专家担任召集人，全部成员均具备履 行审计委员会工作职责的专业知识和经验，且均为不在公司担任高 级管理人员的董事。 2024 年 2 月 23 日，公司第九届董事会第十九次会议审议通过 《关于调整公司董事会专门委员会部分委员的议案》，将第九届董 事会审计委员会成员由章卫东先生（召集人）、汪志刚先生、邢健 先生调整为张岩先生（召集人）、梁波先生、邢健先生。 2024 年 12 月 23 日，公司完成董事会换届工作。同日召开的第十 届董事会第一次会议审议通过《关于选举公司第十届董事会专门委 员会成员的议案》，选举张岩先生、梁波先生、邓蓉女士为第十届 董事会审计委员会成 ...

江中药业股份有限公司（以下简称"公司"）第九届董事会第二十次会议、 第九届监事会第十五次会议、2023 年年度股东大会审议通过《公司 2024 年预 计日常关联交易的议案》，全年预计发生日常关联交易 83,173 万元，实际发生 日常关联交易 60,512 万元，其中，单项实际发生金额超过预计金额达到 300 万 元以上的各类关联交易，合计金额 453 万元。本次单项日常关联交易超出金额 无须提交股东大会审议。 公司独立董事 2025 年第三次专门会议审议通过本关联交易事项，认为公司 发生的日常关联交易建立在关联各方充分协商的基础上，所追认的 2024 年度日 常关联交易是公司基于正常生产经营所需发生的关联交易，在平等、互利基础 上进行，程序合法有效，交易行为真实合理，未损害公司和股东利益。同意将 该议案提交董事会审议。 重要内容提示： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 证券代码：600750 证券简称：江中药业 公告编号：2025-009 江中药业股份有限公司 关于追认 2024 年日常关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏 ...

鉴于 2021 年限制性股票激励计划的部分激励对象因调动、到龄退休、辞职 等原因，已不符合激励条件，根据《关于印发<中央企业控股上市公司实施股权 激励工作指引>的通知（国资考分〔2020〕178 号）》《上市公司股权激励管理 办法》等法律法规及《江中药业 2021 年限制性股票激励计划（2022 年 11 月修 订稿）》的有关规定，同意公司回购 5 名激励对象已获授但尚未解除限售的 149,602 股限制性股票，回购资金总额为 463,738.88 元，资金来源为公司自有 资金。 本次回购注销事项不会对公司的财务状况和经营业绩产生重大影响，且不影 响公司限制性股票激励计划的继续实施，不存在损害公司及全体股东利益的情 形。 江中药业股份有限公司监事会 关于回购注销部分激励对象已获授但尚未解除限售的 限制性股票及调整回购价格事项的核查意见 根据《上海证券交易所股票上市规则》和《上市公司股权激励管理办法》等 相关法律、法规以及《江中药业 2021 年限制性股票激励计划（2022 年 11 月修 订稿）》的有关规定，江中药业股份有限公司监事会审阅了《关于回购注销部分 激励对象已获授但尚未解锁的限制性股票及调整回购价格 ...

Investment Rating - The report maintains an "Overweight" rating for the industry [5] Core Views - The recent issuance of the "Special Action Plan to Boost Consumption" by the Central and State Offices is expected to significantly stimulate consumption, leading to a recovery in the consumer healthcare sector [3][5] - The report highlights that the medical service industry's performance is anticipated to improve due to better expectations and technological upgrades, despite facing challenges in 2024 [5] - The report identifies specific companies that are expected to benefit from these trends, including Aier Eye Hospital, Puren Eye Hospital, Tongce Medical, and others, all rated as "Overweight" [5] Summary by Sections Industry Overview - The report emphasizes the potential for a recovery in consumer healthcare driven by government policies aimed at boosting consumption [3][5] Investment Highlights - The report notes that the medical service sector is experiencing a slowdown in revenue growth due to external pressures, but demand remains strong, suggesting a rebound as economic conditions improve [5] - New surgical techniques and the implementation of supportive policies are expected to stabilize and enhance the average transaction value in consumer healthcare [5] - The home medical device market is projected to benefit from policies encouraging aging-friendly transformations and increased investment in healthcare and elderly care [5] Company-Specific Insights - The report lists several companies with "Overweight" ratings, including Aier Eye Hospital (market cap: 134 billion, projected net profit for 2024: 35.96 billion), Puren Eye Hospital, and others, indicating strong growth potential [6] - Companies like Kefu Medical and Meihua Medical are also highlighted as beneficiaries of the favorable policy environment, although they are not yet rated [5][6]

结构性分化，把握龙头配置价值 ——中药行业2025年2月月报 长城证券产业金融研究院 分析师：刘鹏 执业证书编号：S1070520030002 邮箱：liupeng@cgws.com 分析师：袁紫馨 执业证书编号：S1070122080041 邮箱：yuanzixin@cgws.com 评级：强大于市（维持） 2025.03.03 01 核心观点 核心观点 1、 2024年 中 药 行 业分 化加大 ，头部 效应凸 显，竞 争格局 有望重 塑 2024年多因素影响行业竞争局，头部企业优势集中，华润系（华润三九、东阿阿胶、昆药集团、江中药业）、片仔癀名贵 OTC龙头、 奇 正藏药 院内贴 膏龙头 通过品 牌壁垒 和渠道 优势普 遍实现 稳健增 长，中 小企业 受成本 端压力 、集采 政策、 医保控 费、消费 疲软等 因素共 振 陷 入 亏 损 或利润 同比下 滑，行 业整体 承压， 2025年 业 绩 压 力减弱 下弹性 有望释 放 2、 估 值 与复盘 • 2月中药板块下跌1.15%， 大 幅 跑输 沪深300和 SW 医 药 生 物指数 ，主要 系科技 成长股 资金虹 吸效应 及"AI+医 疗" 关 注 景 ...

Investment Rating - The report maintains a strong investment rating for the biopharmaceutical industry, particularly for the traditional Chinese medicine (TCM) sector, which is expected to benefit from multiple factors in 2025 [2]. Core Insights - The TCM sector is anticipated to experience a gradual reduction in performance pressure in 2025, driven by factors such as improved earnings, favorable policies, decreasing costs, rising demand, and consolidation within the industry [4][6]. - The report identifies five main investment opportunities within the TCM sector, including high-end OTC products, state-owned enterprise reforms, hospital-based TCM, dividend-paying assets, and turnaround situations for struggling companies [4][7]. Summary by Sections 1. Performance Outlook - The TCM sector faced overall revenue decline in 2024, with a total revenue of 270.61 billion yuan, down 3.28% year-on-year, and a net profit of 29.88 billion yuan, down 8.55% year-on-year [10]. - The number of companies forecasting negative net profit growth in 2024 is 22 out of 34, while only 12 companies expect positive growth [16]. 2. Policy Developments - The third batch of national TCM procurement results showed an average price reduction of 63%, but the impact on listed companies is limited due to the small number of affected products [20]. - A new essential drug list is expected to be released in 2025, which may include more TCM products, enhancing their market presence [24]. 3. Cost Factors - The TCM material price index has been declining since July 2024, which is expected to alleviate cost pressures for TCM companies and improve their gross margins starting in 2025 [28]. 4. Demand Dynamics - The recent increase in flu cases has driven demand for related treatment products, leading to a quicker clearance of inventory for cold and cough medications [34]. 5. Competitive Landscape - The TCM industry is experiencing frequent mergers and acquisitions, which are likely to enhance industry concentration and provide performance flexibility for related listed companies [39]. 6. Investment Opportunities - The report highlights five key investment themes: 1. High-end OTC TCM products, particularly those using natural bezoar as a key ingredient, are expected to see improved margins as supply stabilizes [45][54]. 2. State-owned enterprise reforms are anticipated to yield positive changes in management and strategic planning [7]. 3. Hospital-based TCM products are expected to gain market share due to regulatory support [7]. 4. Companies with strong cash flow and high dividend potential are viewed favorably [7]. 5. Companies currently facing challenges are expected to improve as inventory pressures ease [7]. 7. Recommended Stocks - The report suggests monitoring companies such as Kunming Pharmaceutical, Tongrentang, Darentang, Jiangzhong Pharmaceutical, Dong'e Ejiao, China Resources Sanjiu, Yunnan Baiyao, Tianshili, Fangsheng Pharmaceutical, and others for potential investment opportunities [4].

证券代码：600750 证券简称：江中药业 公告编号：2025-001 江中药业股份有限公司 第十届董事会第二次会议决议公告 经与会董事充分研究和讨论，审议通过以下议案： 一、关于公司第二期限制性股票激励计划（草案修订稿）及其摘要的议案 表决情况：5 票同意，0 票反对，0 票弃权，通过本议案。 根据国务院国资委的审核意见并结合公司实际情况，经公司董事会薪酬与考 核委员会事前审议通过，同意对第九届董事会第十七次会议审议通过的公司《第 二期限制性股票激励计划（草案）》及其摘要进行修订。 董事会认为修订后的公司《第二期限制性股票激励计划（草案修订稿）》及 其摘要符合《公司法》《证券法》《上市公司股权激励管理办法》《中央企业控 股上市公司实施股权激励工作指引》等法律法规、规范性文件以及《公司章程》 的有关规定。 关联董事刘为权、徐永前、刘立新、胡凤祥对本议案履行了回避表决程序。 具体详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的《江中 药业第二期限制性股票激励计划（草案修订稿）》《江中药业第二期限制性股票 激励计划（草案修订稿）摘要的公告》。 本议案尚需提交公司股东大会审议。 1 二、关于公 ...

独立董事候选人声明与承诺 本人梁波，已充分了解并同意由提名人江中药业股份有限公司董 事会提名为江中药业股份有限公司第十届董事会独立董事候选人。本 人公开声明，本人具备独立董事任职资格，保证不存在任何影响本人 担任江中药业股份有限公司独立董事独立性的关系，具体声明并承诺 如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法 规、部门规章及其他规范性文件，具有 5 年以上法律、经济、会计、 财务、管理或者其他履行独立董事职责所必需的工作经验。 本人已经参加培训并取得证券交易所认可的相关培训证明材料。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司 规章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定 （如适用）； （三）中国证监会《上市公司独立董事管理办法》、上海证券交 易所自律监管规则以及公司章程有关独立董事任职资格和条件的相 关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去 公职或者退（离）休后担任上市公司、基金管理公司独立董事、独立 监事的通知》的规定（如适用）； （五）中共中央组织部《关于进一 ...

Investment Rating - The report maintains a rating of "Accumulate" for Jiangzhong Pharmaceutical [1] Core Views - Jiangzhong Pharmaceutical's Q3 2024 results show stable profit growth, but the health business needs recovery. The company achieved a revenue of 2.972 billion yuan in the first three quarters of 2024, a year-on-year decrease of 8.19%, while the net profit attributable to shareholders was 634 million yuan, an increase of 7.09% year-on-year [2][3] Financial Performance Summary - Revenue for 2022 was 3.885 billion yuan, with a growth rate of 35.2%. In 2023, revenue is projected at 4.390 billion yuan, reflecting a growth rate of 13.0%. However, a decline of 2.6% is expected in 2024, with revenues estimated at 4.275 billion yuan. The company anticipates a recovery in 2025 and 2026, with revenues of 4.756 billion yuan and 5.425 billion yuan, respectively, representing growth rates of 11.3% and 14.1% [1][5] - The net profit attributable to shareholders for 2022 was 598 million yuan, with a growth rate of 18.3%. The net profit for 2023 is expected to be 708 million yuan, with a growth rate of 18.4%. The company forecasts net profits of 795 million yuan, 902 million yuan, and 1.038 billion yuan for 2024, 2025, and 2026, respectively, with growth rates of 12.3%, 13.4%, and 15.1% [1][5] - The overall gross margin for Q3 2024 decreased by 2.97 percentage points to 63.94%. The gross margins for OTC, prescription drugs, and health products were 72.32%, 43.29%, and 23.62%, respectively, with year-on-year changes of +0.53, -15.39, and -25.32 percentage points [3] Business Segment Performance - The OTC segment generated revenue of 2.335 billion yuan, a year-on-year increase of 2.78%, accounting for 78.57% of total revenue, which is an increase of 6.25 percentage points. The prescription drug segment saw revenue of 365 million yuan, a decline of 25.10%, primarily due to changes in product structure from unsuccessful bids in centralized procurement. The health business generated revenue of 249 million yuan, a significant decrease of 45.73% due to slower expansion and product adjustments [2][3] Future Outlook - The report projects revenues of 4.275 billion yuan, 4.756 billion yuan, and 5.425 billion yuan for 2024, 2025, and 2026, respectively, with corresponding net profits of 795 million yuan, 902 million yuan, and 1.038 billion yuan. The expected P/E ratios for these years are 17.8, 15.7, and 13.7, respectively [3][5]

Investment Rating - The report maintains a "Buy" rating for Jiangzhong Pharmaceutical, with an expected price increase of 5% to 15% relative to the industry index over the next six months [8]. Core Views - The report highlights the confidence in the company's long-term development, as evidenced by the controlling shareholder's plan to increase their stake in the company, with a total investment amount between 60 million and 120 million RMB [2]. - Jiangzhong Pharmaceutical is recognized as a high-dividend and quality OTC enterprise focusing on the gastrointestinal field, with plans for category expansion and channel enhancement to drive revenue growth [2]. - The company is expected to achieve revenues of 4.275 billion, 4.756 billion, and 5.425 billion RMB for 2024, 2025, and 2026 respectively, with corresponding net profits of 795 million, 902 million, and 1.038 billion RMB [2]. Financial Summary - Revenue for 2022 was 3.885 billion RMB, with a year-on-year growth rate of 35.2%. The forecast for 2023 is 4.390 billion RMB, reflecting a growth rate of 13.0%, followed by a slight decline to 4.275 billion RMB in 2024 [1]. - The net profit attributable to the parent company for 2022 was 598 million RMB, with a growth rate of 18.3%. The forecast for 2023 is 708 million RMB, with a growth rate of 18.4%, and is expected to reach 795 million RMB in 2024, reflecting a growth rate of 12.3% [1]. - The report projects a return on equity (ROE) of 17.6% for 2024, increasing to 18.3% by 2026 [1].